D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 87 Citations 29,661 466 World Ranking 7048 National Ranking 326

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Ulrich Germing mainly investigates Internal medicine, Myelodysplastic syndromes, Surgery, Oncology and Leukemia. His Internal medicine research includes themes of Gastroenterology and Pathology. The study incorporates disciplines such as Survival rate, Retrospective cohort study and Pediatrics in addition to Myelodysplastic syndromes.

His Surgery study integrates concerns from other disciplines, such as Azacitidine, Multivariate analysis and Risk factor. His studies in Oncology integrate themes in fields like Survival analysis, Clinical trial, Proportional hazards model and Immunophenotyping. His work in the fields of Leukemia, such as Myelogenous, overlaps with other areas such as Context.

His most cited work include:

  • Revised International Prognostic Scoring System for Myelodysplastic Syndromes (1564 citations)
  • Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. (830 citations)
  • Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia (742 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Internal medicine, Myelodysplastic syndromes, Oncology, Gastroenterology and Bone marrow. He interconnects Surgery and Immunology in the investigation of issues within Internal medicine. Ulrich Germing works mostly in the field of Myelodysplastic syndromes, limiting it down to concerns involving Leukemia and, occasionally, Survival rate.

His research investigates the connection with Oncology and areas like Cytogenetics which intersect with concerns in Karyotype. His Gastroenterology research is multidisciplinary, incorporating elements of Chemotherapy and Phases of clinical research. His work carried out in the field of Bone marrow brings together such families of science as CD34, Haematopoiesis and Cancer research.

He most often published in these fields:

  • Internal medicine (66.56%)
  • Myelodysplastic syndromes (54.02%)
  • Oncology (32.48%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (66.56%)
  • Myelodysplastic syndromes (54.02%)
  • Oncology (32.48%)

In recent papers he was focusing on the following fields of study:

Ulrich Germing spends much of his time researching Internal medicine, Myelodysplastic syndromes, Oncology, Myeloid leukemia and Lower risk. In his study, Salvage therapy is strongly linked to Azacitidine, which falls under the umbrella field of Internal medicine. In his study, which falls under the umbrella issue of Myelodysplastic syndromes, Retrospective cohort study is strongly linked to Survival rate.

His Oncology study also includes

  • Decitabine together with Retinoic acid,
  • Leukemia most often made with reference to Myeloid. His work in Lower risk tackles topics such as European LeukemiaNet which are related to areas like Pediatrics. The various areas that Ulrich Germing examines in his Cohort study include Gastroenterology and Proportional hazards model.

Between 2016 and 2021, his most popular works were:

  • Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study (153 citations)
  • Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (85 citations)
  • Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions (67 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His main research concerns Internal medicine, Myelodysplastic syndromes, Oncology, Myeloid leukemia and Lower risk. His Internal medicine study frequently links to related topics such as Azacitidine. His Myelodysplastic syndromes research is within the category of Bone marrow.

His work deals with themes such as Multivariate analysis, Immunology, Cause of death, Minimal residual disease and Neuroblastoma RAS viral oncogene homolog, which intersect with Oncology. His work in Myeloid leukemia addresses subjects such as Allogeneic transplantation, which are connected to disciplines such as Targeted therapy, Flt3 itd and Allo sct. His Lower risk study incorporates themes from Transfusion independence, Lenalidomide and Quality of life.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Blood (2012)

2252 Citations

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Luca Malcovati;Ulrich Germing;Andrea Kuendgen;Matteo G. Della Porta.
Journal of Clinical Oncology (2007)

1167 Citations

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini.
Journal of Clinical Oncology (2010)

992 Citations

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Detlef Haase;Ulrich Germing;Julie Schanz;Michael Pfeilstöcker.
Blood (2007)

924 Citations

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

Peter Paschka;Richard F. Schlenk;Verena I. Gaidzik;Marianne Habdank.
Journal of Clinical Oncology (2010)

922 Citations

Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen.

Stephanie Kruetzmann;M. Manuela Rosado;Holger Weber;Ulrich Germing.
Journal of Experimental Medicine (2003)

696 Citations

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

Peter Valent;Hans-Peter Horny;John M. Bennett;Christa Fonatsch.
Leukemia Research (2007)

673 Citations

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

Michael Lübbert;Stefan Suciu;Liliana Baila;Björn Hans Rüter.
Journal of Clinical Oncology (2011)

600 Citations

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

Luca Malcovati;Eva Hellström-Lindberg;David Bowen;Lionel Adès.
Blood (2013)

595 Citations

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Julie Schanz;Heinz Tüchler;Francesc Solé;Mar Mallo.
Journal of Clinical Oncology (2012)

440 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ulrich Germing

Guillermo Garcia-Manero

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

Publications: 192

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 178

Pierre Fenaux

Pierre Fenaux

Université Paris Cité

Publications: 160

Mikkael A. Sekeres

Mikkael A. Sekeres

Cleveland Clinic

Publications: 157

Alan F. List

Alan F. List

Precision BioSciences

Publications: 152

David P. Steensma

David P. Steensma

Harvard University

Publications: 129

Ayalew Tefferi

Ayalew Tefferi

Mayo Clinic

Publications: 109

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 97

Ghulam J. Mufti

Ghulam J. Mufti

University of Cambridge

Publications: 94

Jaroslaw P. Maciejewski

Jaroslaw P. Maciejewski

Cleveland Clinic

Publications: 94

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 89

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 85

Torsten Haferlach

Torsten Haferlach

MLL Munich Leukemia Laboratory

Publications: 82

Eva Hellström-Lindberg

Eva Hellström-Lindberg

Karolinska University Hospital

Publications: 82

H. Joachim Deeg

H. Joachim Deeg

Fred Hutchinson Cancer Research Center

Publications: 75

Arnold Ganser

Arnold Ganser

Hannover Medical School

Publications: 73

Trending Scientists

Ozgur B. Akan

Ozgur B. Akan

University of Cambridge

Michael W. Mahoney

Michael W. Mahoney

University of California, Berkeley

Richard A. Robb

Richard A. Robb

Mayo Clinic

Martin Scheringer

Martin Scheringer

ETH Zurich

Tomoyuki Inui

Tomoyuki Inui

Kyoto University

Jerold M. Schultz

Jerold M. Schultz

University of Delaware

Wei Chen

Wei Chen

Huazhong University of Science and Technology

Lex H.T. Van der Ploeg

Lex H.T. Van der Ploeg

MSD (United States)

Daniel H. Nussey

Daniel H. Nussey

University of Edinburgh

Niels Oksbjerg

Niels Oksbjerg

Aarhus University

Jae-Kwan Hwang

Jae-Kwan Hwang

Yonsei University

Christophe Ferrari

Christophe Ferrari

Joseph Fourier University

Robert D. Laird

Robert D. Laird

University of Alabama

Joseph P. Lynch

Joseph P. Lynch

University of California, Los Angeles

Christoph Stein

Christoph Stein

Charité - University Medicine Berlin

James F. Voss

James F. Voss

University of Pittsburgh

Something went wrong. Please try again later.